PP2A inhibition is a common event in colorectal cancer and its restoration using FTY720 shows promising therapeutic potential

Molecular Cancer Therapeutics

Volumn 13, Issue 4, 2014, Pages 938-947

  Cristóbal, Ion ^a   Manso, Rebeca ^b   Rincón, Raúl ^b   Caramés, Cristina ^a   Senin, Clara ^c   Borrero, Aurea ^a   Martínez Useros, Javier ^a   Rodriguez, María ^a   Zazo, Sandra ^b   Aguilera, Oscar ^a   Madoz Gúrpide, Juan ^b   Rojo, Federico ^b   García Foncillas, Jesús ^a  

^a HOSPITAL UNIVERSITARIO FUNDACIÓN JIMÉNEZ DÍAZ   (Spain)

^b 28400 Madrid   (Spain)

^c University Hospital of Vigo   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; CIP2A PROTEIN; FINGOLIMOD; FIRTECAN; FLUOROURACIL; MITOGEN ACTIVATED PROTEIN KINASE 1; OXALIPLATIN; PHOSPHOPROTEIN PHOSPHATASE 2A; PROTEIN KINASE B; SET PROTEIN; TUMOR PROTEIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; AUTOANTIGEN; CHAPERONE; KIAA1524 PROTEIN, HUMAN; MEMBRANE PROTEIN; PHOSPHOPROTEIN PHOSPHATASE 2; PROPANEDIOL DERIVATIVE; SET PROTEIN, HUMAN; SPHINGOSINE; TRANSCRIPTION FACTOR;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER PATIENT; CELL PROLIFERATION; CELL VIABILITY; CLINICAL ARTICLE; CLONOGENESIS; COLORECTAL CANCER; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INACTIVATION; ENZYME INHIBITION; EX VIVO STUDY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; ONCOGENE C MYC; PRIORITY JOURNAL; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; COLORECTAL NEOPLASMS; DRUG EFFECTS; DRUG POTENTIATION; GENE EXPRESSION REGULATION; GENETICS; HT 29 CELL LINE; METABOLISM; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AUTOANTIGENS; CELL LINE, TUMOR; CELL PROLIFERATION; COLORECTAL NEOPLASMS; DRUG SYNERGISM; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE CHAPERONES; HT29 CELLS; HUMANS; MEMBRANE PROTEINS; PROPYLENE GLYCOLS; PROTEIN PHOSPHATASE 2; SIGNAL TRANSDUCTION; SPHINGOSINE; TRANSCRIPTION FACTORS;

EID: 84904003955     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-13-0150     Document Type: Article

References (33)

1. Janssens V, Goris J. Protein phosphatase 2A: a highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling. Biochem J 2001;353:417-39.
2. Janssens V, Goris J, Van Hoof C. PP2A: the expected tumor suppressor. Curr Opin Genet Dev 2005;15:34-41.
3. Mumby M. PP2A: unveiling a reluctant tumor suppressor. Cell 2007;130:21-4.
4. Westermarck J, Hahn WC. Multiple pathways regulated by the tumor suppressor PP2A in transformation. Trends Mol Med 2008;14:152-160.
5. Eichhorn PJ, Creyghton MP, Bernards R. Protein phosphatase 2A regulatory subunits and cancer. BiochimBiophys Acta 2009;1795:1-15.
6. Zhou J, Pham HT, Ruediger R, Walter G. Characterization of the Aalpha and Abeta subunit isoforms of protein phosphatase 2A: differences in expression, subunit interaction, and evolution. Biochem J 2003;369:387-98.
7. Arino J, Woon CW, Brautigan DL, Miller TBJr, Johnson GL. Human liver phosphatase 2A: cDNA and amino acid sequence of two catalytic subunit isotypes. Proc Natl Acad Sci U S A 1988;85:4252-56.
8. Chen J, Martin BL, Brautigan DL. Regulation of protein serine-threonine phosphatase type-2A by tyrosine phosphorylation. Science 1992;257:1261-4.
9. Cristobal I, Garcia-Orti L, Cirauqui C, Alonso MM, Calasanz MJ, Odero MD. PP2A impaired activity is a common event in acute myeloid leukemia and its activation by forskolin has a potent anti-leukemic effect. Leukemia 2011;25:606-14.
10. Perrotti D, Neviani P. Protein phosphatase 2A (PP2A), a drugable tumor suppressor in Ph1(+) leukemias. Cancer Metastasis Rev 2008;27:159-68.
11. Voronkov M, Braithwaite SP, Stock JB. Phosphoprotein phosphatase 2A: a novel druggable target for Alzheimer's disease. Future Med Chem 2011;3:821-33.
12. Kalev P, Sablina AA. Protein phosphatase 2A as a potential target for anticancer therapy. Anticancer Agents Med Chem 2011;11:38-46.
13. Wang SS, Esplin ED, Li JL, Huang L, Gazdar A, Minna J, et al. Alterations of the PPP2R1B gene in human lung and colon cancer. Science 1998;282:284-7.
14. Takagi Y, Futamura M, Yamaguchi K, Aoki S, Takahashi T, Saji S. Alterations of the PPP2R1B gene located at 11q23 in human colorectal cancers. Gut 2000;47:268-71.
15. Ruediger R, Pham HT, Walter G. Alterations in protein phosphatase 2A subunit interaction in human carcinomas of the lung and colon with mutations in the A beta subunit gene. Oncogene 2001;20:1892-9.
16. Tamaki M, Goi T, Hirono Y, Katayama K, Yamaguchi A. PPP2R1B gene alterations inhibit interaction of PP2A-Abeta and PP2A-C proteins in colorectal cancers. Oncol Rep 2004;11:655-9.
17. Tan J, Lee PL, Li Z, Lim YC, Hooi SC, et al. B55b-associated PP2A complex controls PDK1-directed myc signaling and modulates rapamycin sensitivity in colorectal cancer. Cancer Cell 2010;18:459-71.
18. Kumar A, Pandurangan AK, Lu F, Fyrst H, Zhang M, Byun HS, et al. Chemopreventive sphingadienes downregulate Wnt signaling via a PP2A/Akt/GSK3β pathway in colon cancer. Carcinogenesis 2012;33:1726-35.
19. Lin SP, Lee YT, Yang SH, Miller SA, Chiou SH, Hung MC, et al. Colon cancer stem cells resist antiangiogenesis therapy-induced apoptosis. Cancer Lett 2013;328:226-34.
20. Cristobal I, Blanco FJ, Garcia-Orti L, Marcotegui N, Vicente C, Rifon J, et al. SETBP1 overexpression is a novel leukemogenic mechanism that predicts adverse outcome in elderly patients with acute myeloid leukemia. Blood 2010;115:615-625.
21. Wei H, Ashby DG, Moreno CS, Ogris E, Yeong FM, Corbett AH , et al. Carboxymethylation of the PP2A catalytic subunit in Saccharomyces cerevisiae is required for efficient interaction with the B-type subunits Cdc55p and Rts1p. J Biol Chem 2001;276:1570-1577.
22. MacKay KB, Tu Y, Clarke SG. Circumventing embryonic lethality with Lcmt1 deficiency: generation of hypomorphic Lcmt1 mice with reduced protein phosphatase 2A methyltransferase expression and defects in insulin signaling. PLoS One 2013;8:e65967.
23. Teng HW, Yang SH, Lin JK, Chen WS, Lin TC, Jiang JK , et al. CIP2A is a predictor of poor prognosis in colon cancer. J Gastrointest Surg 2012;16:1037-47.
24. Junttila MR, Westermarck J. Mechanisms of MYC stabilization in human malignancies. Cell Cycle 2008;7:592-6.
25. Böckelman C, Koskensalo S, Hagström J, Lundin M, Ristimäki A, Haglund C. CIP2A overexpression is associated with c-Myc expression in colorectal cancer. Cancer Biol Ther 2012;13:289-95.
26. Saydam G, Aydin HH, Sahin F, Selvi N, Oktem G, Terzioglu E , et al. Involvement of protein phosphatase 2A in interferon-alpha-2binduced apoptosis in K562 human chronic myelogenous leukaemia cells. Leuk Res 2003;27:709-717.
27. Neviani P, Santhanam R, Oaks JJ, Eiring AM, Notari M, Blaser BW , et al. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. J Clin Invest 2007;117:2408-21.
28. Kalev P, Simicek M, Vazquez I, Munck S, Chen L, Soin T , et al. Loss of PPP2R2A inhibits homologous recombination DNA repair and predicts tumor sensitivity to PARP inhibition. Cancer Res 2012;72:6414-24.
29. Cristobal I, Cirauqui C, Castello-Cross R, Garcia-Orti L, Calasanz MJ, Odero MD. Downregulation of PPP2R5E is a common event in acute myeloid leukemia that affects the oncogenic potential of leukemic cells. Haematologica 2013;98:e103-104.
30. Barisic S, Schmidt C, Walczak H, Kulms D. Tyrosine phosphatase inhibition triggers sustained canonical serine-dependent NFkappaB activation via Src-dependent blockade of PP2A. Biochem Pharmacol 2010;80:439-447.
31. Nagaoka Y, Otsuki K, Fujita T, Uesato S. Effects of Phosphorylation of Immunomodulatory Agent FTY720 (Fingolimod) on Antiproliferative Activity against Breast and Colon Cancer Cells. Biol Pharm Bull 2008;31:1177-81.
32. Liu Q, Zhao X, Frissora F, Ma Y, Santhanam R, Jarjoura D, et al. FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma. Blood 2008;111:275-284.
33. Saddoughi SA, Gencer S, Peterson YK, Ward KE, Mukhopadhyay A, Oaks J, et al. Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosis. EMBO Mol Med 2013;5:105-21.